(Q34300585)

1 August 2017

1 reference

title

Use of statins in CNS disorders (English)

1 reference

1 August 2017

Cucchiara B

1

1 reference

1 August 2017

Kasner SE

series ordinal

2

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Journal of the Neurological Sciences

1 August 2017

published in

1 reference

1 August 2017

volume

187

1 reference

1 August 2017

issue

1-2

1 reference

1 August 2017

page(s)

81-89

1 reference

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Signaling molecules derived from the cholesterol biosynthetic pathway: mechanisms of action and possible roles in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Current status of risk factors for stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke. A longitudinal study in Eastern Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Cerebrovascular Disease in the Bi-Racial Population of Evans County, Georgia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

The symptomatic carotid plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Are we mortgaging the medical profession?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Pharmacological control of phagocyte function: inhibition of cholesterol accumulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

The effects of diet and lovastatin on regression of fatty streak lesions and on hepatic and intestinal mRNA levels for the LDL receptor and HMG CoA reductase in F1B hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

PROAPOPTOTIC EFFECT OF ATORVASTATIN ON STIMULATED RABBIT SMOOTH MUSCLE CELLS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Esterified Cholesterol Accumulation Induced by Aggregated LDL Uptake in Human Vascular Smooth Muscle Cells Is Reduced by HMG-CoA Reductase Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Increased thromboxane biosynthesis in type IIa hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Platelet Deposition on Eroded Vessel Walls at a Stenotic Shear Rate Is Inhibited by Lipid-Lowering Treatment With Atorvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Interactions of Platelets, Macrophages, and Lipoproteins in Hypercholesterolemia: Antiatherogenic Effects of HMG-CoA Reductase Inhibitor Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Inducible nitric oxide synthase expression in cerebrovascular smooth muscle and neutrophils after traumatic brain injury in immature rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Differential regulation by cytokines of human astrocyte nitric oxide production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Neuroprotective properties of statins in cerebral ischemia and stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Role of Endothelial Dysfunction in Coronary Artery Disease and Implications for Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Cognitive Impairment and Cellular/Vascular Changes in the Cerebral White Mattera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet-activating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Effects of Fluvastatin on Leukocyte–Endothelial Cell Adhesion in Hypercholesterolemic Rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

The pathogenesis of atherosclerosis: a perspective for the 1990s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Role of oxidants in ischemic brain damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Preservation of Endogenous Antioxidant Activity and Inhibition of Lipid Peroxidation as Common Mechanisms of Antiatherosclerotic Effects of Vitamin E, Lovastatin and Amlodipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Intraneuronal beta-amyloid immunoreactivity in the CNS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

The role of cholesterol in the biosynthesis of beta-amyloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Statins and the risk of dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Effects of lovastatin on cognitive function and psychological well-being

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Effects of statins on ischemic stroke: neuroprotection and/or triggering of apoptotic damage?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Comparative tolerability of the HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900529-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-510X(01)00529-9

1 reference

1 August 2017

1 reference